



## AtriCure to Participate in the Goldman Sachs 47th Annual Global Health Care Conference

May 27, 2026

MASON, Ohio--(BUSINESS WIRE)--May 27, 2026-- [AtriCure, Inc. \(Nasdaq: ATRC\)](#), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Goldman Sachs 47<sup>th</sup> Annual Global Health Care Conference.

AtriCure's management is scheduled to participate in a fireside chat on Wednesday, June 10, 2026, at 8:40 a.m. Eastern Standard Time. Interested parties may access a live audio webcast by visiting the "Investors" section of the company's website at <https://ir.atricure.com>.

### About AtriCure

AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 59 million people worldwide. Surgeons around the globe use AtriCure technologies for the treatment of Afib, reduction of Afib related complications and post-operative pain management. AtriCure's Isolator® Synergy™ Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib. AtriCure's AtriClip® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. AtriCure's Hybrid AF™ Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients. AtriCure's cryoICE cryoSPHERE® and cryoXT® probes are cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac, thoracic and amputation procedures. For more information, visit [AtriCure.com](https://www.atricure.com) or follow us on X @AtriCure.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20260527069180/en/): <https://www.businesswire.com/news/home/20260527069180/en/>

Angie Wirick  
AtriCure, Inc.  
Chief Financial Officer  
(513) 755-5334  
[awirick@atricure.com](mailto:awirick@atricure.com)

Marissa Bych  
Gilmartin Group  
Investor Relations  
[marissa@gilmartinir.com](mailto:marissa@gilmartinir.com)

Source: AtriCure, Inc.